The company said, “Adaptive Biotechnologies (ADPT) expects full year revenue for the MRD business to be between $255 million and $265 million. No revenue guidance is provided for the Immune Medicine business. We expect full year total company operating expenses, including cost of revenue, to be between $350 million and $360 million.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Is ADPT a Buy, Before Earnings?
- Adaptive Biotechnologies price target raised to $21 from $20 at Guggenheim
- Adaptive Biotechnologies: Strong MRD Momentum and Path to 2026 Profitability Support Buy Rating
- Adaptive Biotechnologies Reports Strong Preliminary Q4 2025 Growth
- Adaptive Biotechnologies sees Q4 revenue $72M, consensus $59.38M